Solid Biosciences (SLDB) Stock Statistics & Valuation Metrics

Solid Biosciences has a market cap or net worth of $343.19M. The enterprise value is $213.40M.

Solid Biosciences has 77,910,240 shares outstanding. The number of shares has decreased by -2.65% in one year.

Solid Biosciences’s return on equity (ROE) is -0.91 and return on invested capital (ROIC) is -78.89%.

The current PE Ratio of Solid Biosciences is ―. Solid Biosciences’s PEG ratio is 0.04.

In the last 12 months, Solid Biosciences had revenue of 0.00 and earned -124.70M in profits. Earnings per share was -3.06.

In the last 12 months, operating cash flow was -132.38M and capital expenditures -792.00K, giving a free cash flow of -133.17M billion.

Solid Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Solid Biosciences upcoming earnings date is Mar 18, 2026, TBA (Confirmed).

Solid Biosciences as a current ratio of 5.20, with Debt / Equity ratio of 10.07%

In the past 12 months, Solid Biosciences has paid 0.00 in taxes.

Solid Biosciences EV to EBITDA ratio is -0.88, with an EV/FCF ratio of -1.07.

Solid Biosciences has $236.14M in cash and marketable securities with $21.94M in debt, giving a net cash position of $214.21M billion.

Gross margin is -41.01%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Solid Biosciences is $15.10, which is 11.43% higher than the current price. The consensus rating is Strong Buy